122 related articles for article (PubMed ID: 11830536)
1. The CLN3 gene is a novel molecular target for cancer drug discovery.
Rylova SN; Amalfitano A; Persaud-Sawin DA; Guo WX; Chang J; Jansen PJ; Proia AD; Boustany RM
Cancer Res; 2002 Feb; 62(3):801-8. PubMed ID: 11830536
[TBL] [Abstract][Full Text] [Related]
2. CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide.
Puranam KL; Guo WX; Qian WH; Nikbakht K; Boustany RM
Mol Genet Metab; 1999 Apr; 66(4):294-308. PubMed ID: 10191118
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells.
Cianchi F; Papucci L; Schiavone N; Lulli M; Magnelli L; Vinci MC; Messerini L; Manera C; Ronconi E; Romagnani P; Donnini M; Perigli G; Trallori G; Tanganelli E; Capaccioli S; Masini E
Clin Cancer Res; 2008 Dec; 14(23):7691-700. PubMed ID: 19047095
[TBL] [Abstract][Full Text] [Related]
4. CLN3L, a novel protein related to the Batten disease protein, is overexpressed in Cln3-/- mice and in Batten disease.
Narayan SB; Pastor JV; Mitchison HM; Bennett MJ
Brain; 2004 Aug; 127(Pt 8):1748-54. PubMed ID: 15240430
[TBL] [Abstract][Full Text] [Related]
5. Retinal pathology and function in a Cln3 knockout mouse model of juvenile Neuronal Ceroid Lipofuscinosis (batten disease).
Seigel GM; Lotery A; Kummer A; Bernard DJ; Greene ND; Turmaine M; Derksen T; Nussbaum RL; Davidson B; Wagner J; Mitchison HM
Mol Cell Neurosci; 2002 Apr; 19(4):515-27. PubMed ID: 11988019
[TBL] [Abstract][Full Text] [Related]
6. Altered arginine metabolism in the central nervous system (CNS) of the Cln3-/- mouse model of juvenile Batten disease.
Chan CH; Ramirez-Montealegre D; Pearce DA
Neuropathol Appl Neurobiol; 2009 Apr; 35(2):189-207. PubMed ID: 19284480
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer.
Lee CH; Liu M; Sie KL; Lee MS
Anticancer Res; 1996; 16(4A):1805-11. PubMed ID: 8712704
[TBL] [Abstract][Full Text] [Related]
8. C-terminal deletion mutant p21(WAF1/CIP1) enhances E2F-1-mediated apoptosis in colon adenocarcinoma cells.
Elliott MJ; Stilwell A; Dong YB; Yang HL; Wong SL; Wrightson WR; Martin RC; McMasters KM
Cancer Gene Ther; 2002 May; 9(5):453-63. PubMed ID: 11961668
[TBL] [Abstract][Full Text] [Related]
9. Defective lysosomal arginine transport in juvenile Batten disease.
Ramirez-Montealegre D; Pearce DA
Hum Mol Genet; 2005 Dec; 14(23):3759-73. PubMed ID: 16251196
[TBL] [Abstract][Full Text] [Related]
10. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
[TBL] [Abstract][Full Text] [Related]
11. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer.
Liu X; Elojeimy S; El-Zawahry AM; Holman DH; Bielawska A; Bielawski J; Rubinchik S; Guo GW; Dong JY; Keane T; Hannun YA; Tavassoli M; Norris JS
Mol Ther; 2006 Nov; 14(5):637-46. PubMed ID: 16887394
[TBL] [Abstract][Full Text] [Related]
12. Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent.
Chen T; Turner J; McCarthy S; Scaltriti M; Bettuzzi S; Yeatman TJ
Cancer Res; 2004 Oct; 64(20):7412-9. PubMed ID: 15492264
[TBL] [Abstract][Full Text] [Related]
13. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of lysosomal acid phosphatase in CLN3-defective cells and mouse brain tissue.
Pohl S; Mitchison HM; Kohlschütter A; van Diggelen O; Braulke T; Storch S
J Neurochem; 2007 Dec; 103(6):2177-88. PubMed ID: 17868323
[TBL] [Abstract][Full Text] [Related]
15. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons.
Dhar S; Bitting RL; Rylova SN; Jansen PJ; Lockhart E; Koeberl DD; Amalfitano A; Boustany RM
Ann Neurol; 2002 Apr; 51(4):448-66. PubMed ID: 11921051
[TBL] [Abstract][Full Text] [Related]
16. Neural and extraneural expression of the neuronal ceroid lipofuscinoses genes CLN1, CLN2, and CLN3: functional implications for CLN3.
Chattopadhyay S; Pearce DA
Mol Genet Metab; 2000; 71(1-2):207-11. PubMed ID: 11001812
[TBL] [Abstract][Full Text] [Related]
17. Altered gene expression in the eye of a mouse model for batten disease.
Chattopadhyay S; Kingsley E; Serour A; Curran TM; Brooks AI; Pearce DA
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2893-905. PubMed ID: 15326100
[TBL] [Abstract][Full Text] [Related]
18. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
19. Immunochemical localization of the Batten disease (CLN3) protein in retina.
Katz ML; Gao CL; Prabhakaram M; Shibuya H; Liu PC; Johnson GS
Invest Ophthalmol Vis Sci; 1997 Oct; 38(11):2375-86. PubMed ID: 9344361
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells.
Spurgers KB; Coombes KR; Meyn RE; Gold DL; Logothetis CJ; Johnson TJ; McDonnell TJ
Oncogene; 2004 Mar; 23(9):1712-23. PubMed ID: 14647426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
